15 July 2026
15 July 2026
The newly licensed device will be added to Neuraptive’s portfolio, which includes NTX-001, currently in Phase III clinical evaluation.
Spero will hold rights to the antibody in all markets except Mainland China, Hong Kong, Macau, and Taiwan.
Regulatory submission for the device was supported by a multinational, prospective, controlled clinical study.
The open-label trial enrolled patients aged between two and 12 years who have a clinical diagnosis of Dravet syndrome.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
